FED CUTS Fed slashes interest rates by 25 basis points in 2nd consecutive cut IOB - Delayed Quote ? EUR Pharming Group N.V. (0QCO.IL) Follow Compare 0.7563 +0.0235 (+3.21%) At close: 3:14 PM GMT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Pharming Group to participate in November investor conference Leiden, the Netherlands, November 5, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of November: Jefferies London Healthcare Conference 2024, London, U.K., November 19-21Sijmen de Vries, Chief Executive Officer, will present on Wednesday, November 20 at 08:00 GMT/09:00 CET. A live webcast and replay of the presentation will be available in the “Upcoming Events” GlobeNewswire ? 2 days ago PHAR PHGUF 0.00% High Growth Tech And 2 Other Promising Stocks To Watch As global markets navigate a turbulent landscape marked by lower stock performances amid busy earnings reports and mixed economic signals, small-cap stocks have demonstrated resilience compared to their larger counterparts. In this environment, identifying promising investment opportunities requires a keen eye for companies with strong fundamentals and the potential to thrive in sectors like high-growth tech, where innovation can drive significant returns. Simply Wall St. ? 3 days ago PHAR PHGUF 0.00% PRS.MC Pharming Group (PHGUF) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... Pharming Group (PHGUF) reports a 12% revenue increase in Q3 2024, driven by Ruconest and Joenja, while navigating operational losses and market expansion efforts. GuruFocus.com ? 13 days ago PHARM.AS Pharming Group reports third quarter 2024 financial results and provides business update Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST? and Joenja? revenue growthRUCONEST? third quarter revenue increased by 6% to US$63.6 million, compared to the third quarter 2023Joenja? (leniolisib) third quarter revenue increased by 72% to US$11.2 million, compared to the third quarter 2023 First nine months total revenues increased by 25% to US$204.5 million, compared to the first nine months 2023On t GlobeNewswire ? 14 days ago PHAR PHGUF 0.00% October 2024's Promising Penny Stocks to Watch As global markets continue to navigate a complex economic landscape, the S&P 500 has seen gains driven by utilities and real estate, while small-cap indices like the Russell 2000 have outperformed. In this context, penny stocks—often representing smaller or newer companies—remain a compelling area for investors seeking growth opportunities at lower price points. Despite being considered an outdated term, these stocks can offer significant potential when supported by strong financials and... Simply Wall St. ? 16 days ago PHAR PHGUF 0.00% FITGF Pharming Group to report third quarter 2024 financial results on October 24 Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2024 financial results, for the period ended September 30, on Thursday, October 24, 2024.Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on October 24, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in inform GlobeNewswire ? 28 days ago PHAR PHGUF 0.00% Novavax (NVAX) Moves 19.2% Higher: Will This Strength Last? Novavax (NVAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. Zacks ? last month NVAX PHARM.AS Pharming announces marketing authorization in the U.K. for Joenja? (leniolisib) For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, September 26, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Joenja? (leniolisib) for the treatment of activated pho GlobeNewswire ? last month PHAR PHGUF 0.00% Pharming Group to participate in September investor conferences Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the U.S. in the month of September: 2024 Wells Fargo Healthcare Conference, Boston, September 4-6Sijmen de Vries, Chief Executive Officer, will participate in a fireside chat question and answer session on Friday, September 6 at 08:45 AM ET/14:45 CET. A live webcast and replay of the pr GlobeNewswire ? 2 months ago PHAR PHGUF 0.00% Pharming Group reports second quarter and first half 2024 financial results and provides business update Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST? and Joenja? revenue growthRUCONEST? second quarter revenue increased by 23% to US$63.0 million, compared to the second quarter 2023Joenja? (leniolisib) second quarter revenue increased by 16% to US$11.1 million, compared to the first quarter 2024 First half total revenues increased by 33% to US$129.7 million, compared to the first half 2023On track for 2024 tota GlobeNewswire ? 3 months ago PHAR PHGUF 0.00% Pharming Group to report second quarter and first half 2024 financial results on August 1 Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2024 financial results, for the period ended June 30, on Thursday, August 1, 2024.Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on August 1, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in in GlobeNewswire ? 3 months ago PHAR PHGUF 0.00% Shareholders in Pharming Group (AMS:PHARM) are in the red if they invested a year ago The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that... Simply Wall St. ? 4 months ago PHAR PHGUF 0.00% Pharming Group to participate in June investor conferences Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of June: Jefferies Healthcare Conference, New York, USA, June 5-6, 2024Sijmen de Vries, Chief Executive Officer, will present on Wednesday, June 5 at 10:30EDT/16:30CEST. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of GlobeNewswire ? 5 months ago PHAR PHGUF 0.00% Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union Leiden, the Netherlands, May 30, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today an update on the ongoing review of its Marketing Authorisation Application (MAA) for leniolisib for the treatment of adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta syndrome (APDS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Following the May GlobeNewswire ? 5 months ago PHAR PHGUF 0.00% Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.The shareholders approved the proposals to reappoint Ms. Barbara Yanni (agenda item 4.a) and Mr. Mark Pykett (agenda item 4.b), upon binding recommendation of the Board of Directors, as Non-Executive Directors for a period of four years. In addition, the proposals for the GlobeNewswire ? 5 months ago PHAR PHGUF 0.00% Pharming Group to participate in May investor conference Leiden, the Netherlands, May 20, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of May: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, New York, May 20, 2024Michael Levitan, VP Investor Relations and Corporate Communications will present on Monday, May 20 at 09:30 EDT/15:30 CET. For more information about this conference, or to schedule a GlobeNewswire ? 5 months ago PHAR PHGUF 0.00% Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025 THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE IMMEDIATELY FROM THEIR STOCKBROKER, SOLICITOR, ACCOUNTANT OR OTHER INDEPENDENT FINANCIAL OR LEGAL ADVISER. THIS NOTICE IS NOT FOR DISTRIBUTION IN OR TO ANY PERSON LOCATED IN ANY JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.Leiden, the Netherlands, 15 May 2024: Pharming G GlobeNewswire ? 5 months ago PHAR PHGUF 0.00% Pharming Group reports first quarter 2024 financial results and provides business update First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja? and revenue growth of RUCONEST?RUCONEST? revenues increased by 8% to US$46.0 million, compared to the first quarter 2023Joenja? (leniolisib) revenue of US$9.6 million, a 21% increase compared to the fourth quarter of 2023On track for 2024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth)Overall cash and marketable securitie GlobeNewswire ? 5 months ago PHAR PHGUF 0.00% Pharming Group to report first quarter 2024 financial results on May 8 Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results, for the period ended March 31, on Wednesday, May 8, 2024. Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on May 8, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a un GlobeNewswire ? 6 months ago PHAR PHGUF 0.00% Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD?) 2024 Rare Impact Awards Recognition given for achievement in commercializing Joenja? (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders (NORD?) at the Rare Impact Awards on June 8, 2024. The Rare Impact Awards h GlobeNewswire ? 6 months ago PHAR PHGUF 0.00% Performance Overview Trailing total returns as of 11/7/2024, which may include dividends or other distributions. Benchmark is AEX-Index Return 0QCO.IL AEX-Index YTD -27.42% +11.66% 1-Year -34.55% +19.47% 3-Year -5.47% +7.18%
